VICTOSA PEN PR LIRAGLUTIDE 2 6 MG 3 ML ( 2 pens )

Remedial signs. Is demonstrated in the treatment of grown-up with diabetes mellitus sort 2 (Dm2) in mix with: · Metformin or a sulfonylurea in those patients with inadequate glycemic control regardless of maximal endured measurements of metformin on the other hand sulfonylurea monotherapy. · Metformin and a sulphonylurea or metformin what's more a thiazolidinedione (glitazone) in patients with inadequate glycemic control notwithstanding of double treatment. Need visa Inspection and patients must have a BMI ≥30 kg/ m2. Pharmacokinetics Mechanism of Action 1 and GLP-1 (glucagon-like peptide sort I), which expands insulin emission glucagon and abatements subordinately glucose. Delays the purging Liraglutide has appeared equivalent to glimepiride and somewhat higher insulin glargine and exenatide, despite the fact that The clinical significance is low. Produces equivalent decline weight to exenatide, more noteworthy at benchmark furthermore in patients with high-mass record body. Suspensions because of unfriendly impacts and security profile is like exenatide. The occurrence of hypoglycemia is low, expanding at the point when joined with sulfonylureas. There are vulnerabilities about their wellbeing cardiovascular, thyroid activity, pancreatitis furthermore immunogenicity. No data of long haul wellbeing. There is no viability information in diabetic difficulties or dem